

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Cohance Lifesciences appoints Umang Vohra as Executive Chairman and Group CEO

27 April 2026 | News

Former Cipla CEO to lead the next phase of transformation and growth at Cohance



Hyderabad-based Cohance Lifesciences, a technology-driven, integrated CDMO platform specialising in complex chemistry, ADCs, oligonucleotides, advanced API development and performance materials, has announced the appointment of Umang Vohra as Executive Chairman, effective May 1, 2026 and Group CEO, effective May 20, 2026.

Vohra succeeds Vivek Sharma, who steps down as Executive Chairman for personal reasons. Sharma will continue to be with Cohance as an Advisor for the next 9 months and will support a smooth transition.

The appointment of Vohra reflects a deliberate, strategic decision taken by the Board, to bring in a leader whose profile is specifically suited to the demands of the company's transformation and its next phase of growth.

Vohra is one of the most accomplished leaders in the pharmaceutical industry. Over a career spanning more than three decades, he has led large, complex, global businesses through periods of strategic transformation while maintaining an unwavering focus on customers, quality and operational excellence.

Most recently, as CEO and Managing Director of Cipla Limited, Vohra led the company's transformation over the last decade to build a diversified global pharmaceutical enterprise. Having worked in and transformed two very large and respected Pharma companies in India, Vohra brings an owner-mindset and vast experience in business to the Cohance platform.